The share price of drug distribution firm McKesson Corp (NYSE:MCK) has completely missed the recent stock market rally. Yet its operating fundamentals remain strong and health care reform efforts should breathe further life into its growth prospects.

IN PICTURES: World's Greatest Investors

First Quarter Review
First quarter sales ended June 30 and rose 3% to $27.5 billion. Core distribution revenue accounted for the vast majority of sales (97.2%) and reported a 3% increase. This area consists of acting as a middleman between pharmaceutical firms such as Merck (NYSE:MCK) and distributing drugs to hospitals and drugstores such as HMA (NYSE:HMA) and CVS Caremark (NYSE:CVS),

McKesson also operates a small but very profitable technology solutions segment that sells software and supply chain know-how to help its core customer base operate more efficiently. This unit only reported a 2% rise in the top line but accounted for 11.2% of total divisional operating profits.

Total company operating income was $474 million and grew 3% as gross profits improved but SG&A costs increase more rapidly than sales. Net income also improved 3% to $298 million, or $1.12 per diluted share.

Outlook
Analysts currently project full-year sales growth of 3% to a hair under $112 billion. Management expects earnings between $4.72 and $4.92 per diluted share. However, net income tends to understate McKesson's impressive cash flow generation capabilities. For example, last year earnings were $4.58 but free cash flow exceeded $7 per diluted share.

The Bottom Line
McKesson's first quarter results were respectable and its cash flow generation has allowed for a steady stream of share buybacks and dividend increases. The balance sheet is also strong, with cash on hand in excess of long-term debt for a net cash position.

Yet for some reason, the share price has traded down significantly recently and is very close to its lows over the past year. The forward P/E is now only 12.3, if the company reaches the midpoint of its guidance. The free cash flow multiple will be much lower as long as McKesson continues to efficiently manage its working capital and keep capex low.

This is a very reasonable entry level given McKesson's operations continue to grow and healthcare reform efforts will add millions of new patients into the industry over the coming few years. Rival AmerisourceBergen (NYSE:ABC) is also worth a look, though its stock price has held up as of late. (Want more on evaluating medical companies? Check out Measuring The Medicine Makers.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  2. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  3. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  4. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  5. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  6. Stock Analysis

    Analyzing Sprint Corp's Return on Equity (ROE) (S)

    Learn about Sprint's return on equity. Find out why its ROE is negative and how asset turnover and financial leverage impact ROE relative to Sprint's peers.
  7. Stock Analysis

    Why Alphabet is the Best of the 'FANGs' for 2016

    Alphabet just impressed the street, but is it the best FANG stock?
  8. Investing News

    A 2016 Outlook: What January 2009 Can Teach Us

    January 2009 and January 2016 were similar from an investment standpoint, but from a forward-looking perspective, they were very different.
  9. Mutual Funds & ETFs

    3 Vanguard Equity Fund Underperformers

    Discover three funds from Vanguard Group that consistently underperform their indexes. Learn how consistent most Vanguard low-fee funds are at matching their indexes.
  10. Investing News

    Alphabet Earnings Beat Expectations (GOOGL, AAPL)

    Alphabet's earnings crush analysts' expectations; now bigger than Apple?
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center